HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
00013.HK stock price ended at $23.24 on 木曜日, after rising 3.47%
On the latest trading day Jan 08, 2026, the stock price of 00013.HK rose by 3.47%, climbing from $22.62 to $23.24. Throughout the session, the stock experienced a volatility of 4.07%, with prices fluctuating between a daily low of $22.58 and a high of $23.50. Alongside this price increase, trading volume also rose by 6.1M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 9.3M shares were traded, amounting to a market value of approximately --.